These data provide a proof of principle for pharmacologic downregulation of IFNAR1 to be used against acute life-threatening inflammatory conditions where the concerns for attenuated anti-viral or anti-tumor defenses are secondary. The gene discussed is IFNAR1; the disease is neoplasm.